Подписаться
Виктор СТУСЬ , Viktor Stus , V Stus
Виктор СТУСЬ , Viktor Stus , V Stus
Dnipro state medical univercity
Подтвержден адрес электронной почты в домене dmu.edu.ua - Главная страница
Название
Процитировано
Процитировано
Год
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ...
New England Journal of Medicine 380 (12), 1116-1127, 2019
28742019
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open …
T Powles, ER Plimack, D Soulières, T Waddell, V Stus, R Gafanov, ...
The Lancet Oncology 21 (12), 1563-1573, 2020
6182020
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
TE Hutson, V Lesovoy, S Al-Shukri, VP Stus, ON Lipatov, AH Bair, ...
The Lancet Oncology 14 (13), 1287-1294, 2013
4512013
RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem …
J Motsch, C Murta de Oliveira, V Stus, I Köksal, O Lyulko, HW Boucher, ...
Clinical Infectious Diseases 70 (9), 1799-1808, 2020
3232020
Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I …
KS Kaye, T Bhowmick, S Metallidis, SC Bleasdale, OS Sagan, V Stus, ...
Jama 319 (8), 788-799, 2018
3102018
Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a phase 2/3 …
KS Kaye, LB Rice, AL Dane, V Stus, O Sagan, E Fedosiuk, AF Das, ...
Clinical Infectious Diseases 69 (12), 2045-2056, 2019
1352019
Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ...
Journal of Clinical Oncology 41 (18), 3339-3351, 2023
1282023
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor …
BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ...
Journal of Clinical Oncology 37 (15_suppl), 4500-4500, 2019
1272019
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of …
BI Rini, ER Plimack, V Stus, T Waddell, R Gafanov, F Pouliot, D Nosov, ...
Journal of Clinical Oncology 39 (15_suppl), 4500-4500, 2021
1262021
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
ER Plimack, BI Rini, V Stus, R Gafanov, T Waddell, D Nosov, F Pouliot, ...
Journal of Clinical Oncology 38 (15_suppl), 5001-5001, 2020
762020
Axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a randomized phase III trial
TE Hutson, S Al-Shukri, VP Stus, ON Lipatov, Y Shparyk, AH Bair, ...
Clinical genitourinary cancer 15 (1), 72-76, 2017
642017
Екологія довкілля та безпека життєдіяльності населення у промислових регіонах України
АМ Сердюк, ВП Стусь, ВІ Ляшенко
Дніпропетровськ: Пороги, 2011
492011
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.
BI Rini, ER Plimack, V Stus, R Gafanov, T Waddell, D Nosov, F Pouliot, ...
Journal of Clinical Oncology 41 (17_suppl), LBA4501-LBA4501, 2023
422023
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
L Albiges, H Gurney, V Atduev, C Suarez, MA Climent, D Pook, ...
The Lancet Oncology 24 (8), 881-891, 2023
392023
Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma
J Bedke, BI Rini, ER Plimack, V Stus, R Gafanov, T Waddell, D Nosov, ...
European Urology 82 (4), 427-439, 2022
392022
Охрана окружающей среды и человека в уранодобывающих регионах
ВИ Ляшенко, ОВ Люлько, ВП Стусь
Новини науки Придніпров’я. Серія: Інженерні науки, 37-46, 2003
302003
Axitinib versus sorafenib as first‑line therapy in patients with metastatic renal cell carcinoma (mRCC).
TE Hutson, J Gallardo, V Lesovoy, S Al-Shukri, V Stus, AH Bair, ...
Journal of clinical Oncology 31 (6_suppl), LBA348-LBA348, 2013
292013
RESTORE-IMI 1: a multicenter, randomized, double-blind, comparator-controlled trial comparing the efficacy and safety of imipenem/relebactam versus colistin plus imipenem in …
J Motsch, C De Oliveira, V Stus, I Koksal, O Lyulko, H Boucher
Madrid: European Congress of Clinical Microbiology & Infectious Diseases, 2018
282018
Intravenous fosfomycin (ZTI-01) for the treatment of complicated urinary tract infections (cUTI) including acute pyelonephritis (AP): results from a multi-center, randomized …
KS Kaye, LB Rice, A Dane, V Stus, O Sagan, E Fedosiuk, A Das, ...
Open Forum Infectious Diseases 4 (suppl_1), S528-S528, 2017
232017
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.
T Powles, ER Plimack, V Stus, RA Gafanov, RE Hawkins, D Nosov, ...
Journal of Clinical Oncology 37 (7_suppl), 543-543, 2019
222019
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20